Midza (Lacosamide)

Lacosamide, the active ingredient in Midza, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset and focal seizures in patients with epilepsy. GNH USA supplies Midza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that targets seizure activity in the central nervous system.

- Partial‑onset seizures: Reduces seizure frequency in patients experiencing these focal events. - Focal onset seizures: Controls seizure activity originating from a specific brain region. - Epilepsy: Provides adjunctive therapy to improve overall seizure management in diagnosed epilepsy.

Lacosamide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: Transient feeling of light‑headedness. - Nausea: Mild to moderate stomach upset. - Headache: Occasional tension‑type headache. - Fatigue: Generalized tiredness. - Blurred vision: Temporary visual disturbances. - Diplopia: Double vision in some patients.

Serious or Rare Side Effects: - Cardiac arrhythmia: Irregular heart rhythm, especially with rapid dose escalation. - Suicidal thoughts: Emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: Elevated liver enzymes indicating possible liver stress. - Respiratory depression: Marked slowing of breathing, particularly with concomitant CNS depressants.

Before initiating therapy with Lacosamide, consider the following safety measures.

- Renal impairment: Adjust dosing in patients with reduced kidney function. - Hepatic impairment: Monitor liver function tests regularly. - Concomitant CNS depressants: Use caution when combined with other sedating agents. - Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. - Driving or operating machinery: Advise patients to avoid hazardous activities until they know how the drug affects them. - Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): May reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., oxcarbazepine, lamotrigine): Increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Alcohol: Enhances central nervous system depression. - CNS depressants (e.g., benzodiazepines, opioids): May increase sedation and respiratory depression. - Hormonal contraceptives: Potential reduction in contraceptive effectiveness; advise alternative methods.